Glaucoma medical treatment: philosophy, principles and practice. (Q30327343)

18 June 2017

1 reference

title

Glaucoma medical treatment: philosophy, principles and practice. (English)

1 reference

18 June 2017

Migdal C

1 reference

18 June 2017

publication date

1 June 2000

1 reference

18 June 2017

1 reference

18 June 2017

volume

14 ( Pt 3B)

1 reference

18 June 2017

page(s)

515-518

1 reference

The mechanism of timolol in lowering intraocular pressure. In the normal eye.

18 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

Intraocular pressure and glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

A Clinical Trial of Metipranolol, a Noncardioselective Beta-Adrenergic Antagonist, in Ocular Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

Ocular Beta-Blockers and Systemic Effects

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

Prostaglandin-induced iridial pigmentation in primates

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

Effects of brimonidine on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

Effect of brimonidine tartrate on ocular hemodynamic measurements

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

Duration of effect of pilocarpine gel

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

Pilocarpine ocuserts. Long-term clinical trials and selected pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.138

7 January 2021

Identifiers

DOI

10.1038/EYE.2000.138

1 reference

Dimensions Publication ID

18 June 2017

1008244478

0 references

1 reference